RocketVax

RocketVax AG, founded in 2020 in Basel, Switzerland, operates in the biopharmaceutical industry with a focus on developing advanced vaccines. The company specializes in creating live attenuated SARS CoV 2 vaccines that trigger comprehensive immune responses, including antibodies and T cells, to combat current and future virus variants. Unlike first-generation vaccines, RocketVax's solutions offer robust protection against new infections and prevent the transmission and spread of the virus. The company's innovative nasal vaccine can shut down Covid 19 infections at their initial entry points in the nose and throat, as demonstrated by promising animal studies reported by CNN in April 2023. RocketVax serves a global market, targeting healthcare providers and institutions focused on pandemic preparedness and public health. The business model revolves around research and development, clinical trials, and commercialization of its vaccine products. Revenue is generated through the sale of vaccines and potential licensing agreements. RocketVax is committed to combining scientific and business expertise to ensure long-term patient well-being and sustainability.

Keywords: biopharmaceutical, vaccines, SARS CoV 2, immune response, nasal vaccine, Covid 19, pandemic preparedness, public health, clinical trials, commercialization.